Evaluation of TRAF6 in a large multiancestral lupus cohort

Objective Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with significant immune system aberrations resulting from complex heritable genetics as well as environmental factors. We undertook to study the role of TRAF6 as a candidate gene for SLE, since it plays a major role i...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 64; no. 6; pp. 1960 - 1969
Main Authors Namjou, Bahram, Choi, Chan-Bum, Harley, Isaac T. W., Alarcón-Riquelme, Marta E., Kelly, Jennifer A., Glenn, Stuart B., Ojwang, Joshua O., Adler, Adam, Kim, Kwangwoo, Gallant, Caroline J., Boackle, Susan A., Criswell, Lindsey A., Kimberly, Robert P., Brown, Elizabeth E., Edberg, Jeffrey, Alarcón, Graciela S., Stevens, Anne M., Jacob, Chaim O., Gilkeson, Gary S., Kamen, Diane L., Tsao, Betty P., Anaya, Juan-Manuel, Kim, Eun-Mi, Park, So-Yeon, Sung, Yoon-Kyoung, Guthridge, Joel M., Merrill, Joan T., Petri, Michelle, Ramsey-Goldman, Rosalind, Vilá, Luis M., Niewold, Timothy B., Martin, Javier, Pons-Estel, Bernardo A., Vyse, Timothy J., Freedman, Barry I., Moser, Kathy L., Gaffney, Patrick M., Williams, Adrienne H., Comeau, Mary E., Reveille, John D., Kang, Changwon, James, Judith A., Scofield, R. Hal, Langefeld, Carl D., Kaufman, Kenneth M., Harley, John B., Bae, Sang-Cheol
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.06.2012
Wiley
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN0004-3591
2326-5191
1529-0131
1529-0131
2326-5205
DOI10.1002/art.34361

Cover

More Information
Summary:Objective Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with significant immune system aberrations resulting from complex heritable genetics as well as environmental factors. We undertook to study the role of TRAF6 as a candidate gene for SLE, since it plays a major role in several signaling pathways that are important for immunity and organ development. Methods Fifteen single‐nucleotide polymorphisms (SNPs) across TRAF6 were evaluated in 7,490 SLE patients and 6,780 control subjects from different ancestries. Population‐based case–control association analyses and meta‐analyses were performed. P values, false discovery rate q values, and odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated. Results Evidence of associations was detected in multiple SNPs. The best overall P values were obtained for SNPs rs5030437 and rs4755453 (P = 7.85 × 10−5 and P = 4.73 × 10−5, respectively) without significant heterogeneity among populations (P = 0.67 and P = 0.50, respectively, in Q statistic). In addition, SNP rs540386, which was previously reported to be associated with rheumatoid arthritis (RA), was found to be in linkage disequilibrium with these 2 SNPs (r2 = 0.95) and demonstrated evidence of association with SLE in the same direction (meta‐analysis P = 9.15 × 10−4, OR 0.89 [95% CI 0.83–0.95]). The presence of thrombocytopenia improved the overall results in different populations (meta‐analysis P = 1.99 × 10−6, OR 0.57 [95% CI 0.45–0.72], for rs5030470). Finally, evidence of family‐based association in 34 African American pedigrees with the presence of thrombocytopenia was detected in 1 available SNP (rs5030437) with a Z score magnitude of 2.28 (P = 0.02) under a dominant model. Conclusion Our data indicate the presence of association of TRAF6 with SLE, consistent with the previous report of association with RA. These data provide further support for the involvement of TRAF6 in the pathogenesis of autoimmunity.
Bibliography:European Science Foundation (within the framework of the Research Network Project BIOLUPUS) - No. 07-RNP-083
Korea Research Program for New Drug Target Discovery - No. 20090083335
Arthritis National Research Foundation (Eng Tan Scholar award)
istex:3A686000187A59A151A6FA5476FFEBACA143B387
Alliance for Lupus Research
NIH - No. R37-AI-024717; No. AI-063622; No. AI-071651; No. U19-AI-082714; No. P01-AI-083194; No. R01-AR-042460; No. AR-043274; No. AR-043814; No. AR-044804; No. P50-AR-048940; No. AR-052300; No. AR-053483; No. AR-058554; No. AR-060366; No. AR-42525; No. AR-43727; No. N01-AR-062277; No. CA-141700-01; No. GM-063483; No. HD-07463; No. K08-AI-083790; No. K24-AR-002138; No. M01-RR-00079; No. P01-AR-049084; No. P30-DK-42086; No. P60-AR-049459; No. P60-AR-053308; No. P60-2-AR-030692; No. R01-AR-33062; No. R21-AI-070304; No. P20-RR-015577; No. P20-RR-020143; No. RR-031152; No. UL1-RR-024999; No. UL1-RR-025005; No. UL1-RR-025741; No. UL1-RR-029882; No. 5UL1-RR-025777
Swedish Research Council
Alliance for Lupus Research (Target Identification in Lupus grant)
King Gustaf V's 80th Jubilee Foundation
Kirkland Scholar Program
US Department of Veterans Affairs
Swedish International Development Agency
ark:/67375/WNG-KMR9MPJS-T
Lupus Foundation of America
Federico Wilhelm Agricola Foundation (research grant)
Korean Healthcare Technology Research and Development Project - No. A080588
Lupus Research Institute (Novel Research grant)
US Department of Defense - No. PR094002
National Research Foundation of Korea - No. 2010-0014162
Swedish Association Against Rheumatism
ArticleID:ART34361
Drs. Namjou and Choi contributed equally to this work.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:0004-3591
2326-5191
1529-0131
1529-0131
2326-5205
DOI:10.1002/art.34361